



Press Release March 29, 2021

## **Genovis CFO has resigned**

**Genovis AB's (publ) Chief Financial Officer (CFO) Johny Humaloja has resigned from his position to take on new challenges.**

Johny has been employed by Genovis since 2019 and he will continue in his current role during the notice period. A process to recruit a new CFO will be initiated immediately.

“During his time at Genovis, Johny has contributed to the development of the Group's financial management. I would like to thank him for his contribution to Genovis and wish him good luck in his new endeavors,” says Fredrik Olsson, CEO of Genovis

For more information, please contact: Fredrik Olsson, CEO, Genovis AB,  
Telephone: +46 (0)46-10 12 33, Email: [fredrik.olsson@genovis.com](mailto:fredrik.olsson@genovis.com)

**Genovis'** business concept is to apply its knowledge and imagination to design and provide innovative tools for the development of the drugs of the future. Today Genovis sells several enzyme products known as SmartEnzymes™ all over the world in innovative product formats that facilitate development and quality control of biological drugs. The Group consists of Genovis AB and the wholly owned subsidiary Genovis Inc. (US). Genovis shares are listed on NASDAQ First North Stockholm and Erik Penser Bank is the Company's Certified Adviser, [certifiedadviser@penser.se](mailto:certifiedadviser@penser.se), tel: +46 (0)8-463 83 00.